ArticleHuman vaccines & immunotherapeutics2026
Economic evaluation of 22 HPV vaccination strategies to minimize the risk of penile, anal, and oropharyngeal cancers in Chinese males: A Markov model analysis.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Males can benefit significantly from human papillomavirus (HPV) vaccination. This study developed a decision-Markov model to evaluate the lifetime effectiveness and cost-effectiveness of 22 HPV vaccination strategies for preventing penile, anal, and oropharyngeal cancers. From a healthcare system perspective, vaccination strategies targeting males aged 14 and 40 were compared against no vaccination. Key parameters, including disease progression probabilities, cancer incidence, health state utilities, and direct medical costs, were sourced from the published literature and national databases. We calculated the number of cancer cases and deaths under different strategies and compared their cost-effectiveness. Results demonstrated that male vaccination is highly cost-effective. Vaccinating 14-y-old males averted between 73,724 and 416,654 cancer cases and between 1,102 and 6,229 deaths, depending on the vaccine valency and coverage rate. Similarly, strategies targeting 40-y-old males demonstrated substantial benefits. Overall, 20 of the 22 strategies were deemed highly cost-effective against a willingness-to-pay threshold of three times the national gross domestic product per capita. Sensitivity analysis confirmed the results' robustness. This study provides economic evidence to inform national HPV vaccination policies, demonstrating that including males, particularly adolescents, in vaccination programs represents a cost-effective investment for reducing the burden of HPV-associated cancers in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.